# Role of Interim 18F-FLT PET/CT for Outcome Prediction in Pancreatic Adenocarcinoma

> **NCT03318497** · PHASE2 · COMPLETED · sponsor: **University of Texas Southwestern Medical Center** · enrollment: 6 (actual)

## Conditions studied

- Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** 3'-deoxy-3'-[F-18] fluorothymidine: [F-18]FLT
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Positron Emission Tomography
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT03318497
- **Lead sponsor:** University of Texas Southwestern Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-11
- **Primary completion:** 2021-06-15
- **Final completion:** 2021-06-15
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2022-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03318497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03318497, "Role of Interim 18F-FLT PET/CT for Outcome Prediction in Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03318497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*